EUCTR2010-022155-33-GB进行中（未招募）1 期
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 125
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients must meet all of the following conditions to be eligible for enrollment into the study:
- •1. Age =18 years.
- •2. Karnofsky performance score of =60 (Eastern Cooperative Oncology Group [ECOG] performance score of 0, 1, or 2).
- •3. Histologically confirmed diagnosis of B-cell iNHL, with histological subtype limited to the following based on criteria established by the World Health Organization (WHO) 2008 classification of tumors of haematopoietic and lymphoid tissues:
- •- Follicular lymphoma (FL) Grade 1, 2, or 3a
- •- Small lymphocytic lymphoma (SLL) with absolute lymphocyte count <5 x 10^9/L at the time of diagnosis and on baseline laboratory assessment performed within 4 weeks prior to the start of study drug administration
- •- Lymphoplasmacytoid lymphoma (LPL) with or without associated Waldenstroms Macroglobulinemia (WM)
- •- Marginal zone lymphoma (MZL) (splenic, nodal, or extranodal)
- •4. Histological materials documenting diagnosis of lymphoma available for review.
- •5. Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of =1 lesion that measures >2 cm in the longest dimension [LD] and =1.0 cm in the longest perpendicular dimension [LPD] as assessed by CT or MRI)
- •6. Prior treatment with =2 prior chemotherapy- or immunotherapy-based regimens for iNHL.
- •7. Prior treatment with rituximab and with an alkylating agent (eg, bendamustine, cyclophosphamide, ifosfamide, chlorambucil, melphalan, busulfan, nitrosoureas) for iNHL.
- •8. Lymphoma that is refractory to rituximab and to an alkylating agent. Please refer to Study Protocol section 4.1.1 for the definition of refractoriness.
- •9. Discontinuation of all other therapies (including radiotherapy or chemotherapy) for the treatment of iNHL =3 weeks before initiation of study treatment (Visit 2).
- •10. All acute toxic effects of any prior antitumor therapy resolved to Grade =1 before initiation of study treatment (Visit 2) (with the exception of alopecia [Grade =2 permitted], neurotoxicity [Grade =2 permitted], or bone marrow parameters noted in Table 1 of protocol section 4.1.1 [Grade =2 permitted]).
- •11. Required baseline laboratory data (within 4 weeks prior to start of study drug administration) as shown in Table 1 (see Study Protocol section 4.1.1).
- •12. For men and women of childbearing potential (ie, patients who are not postmenopausal or surgically sterile), willingness to abstain from sexual intercourse or employ an effective method of contraception during the study drug administration and follow-up periods.
- •13. Willingness and ability to provide written informed consent and to comply with scheduled visits, drug administration plan, imaging studies and contrast dye administration, laboratory tests, other study procedures, and study restrictions.
- •14. Evidence of a personally signed informed consent indicating that the patient is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, possible side effects, potential risks and discomforts, and other pertinent aspects of study participation.
排除标准
- •The presence of any of the following conditions will exclude a patient from study enrollment:
- •1. Central nervous system or leptomeningeal lymphoma.
- •2. Known histological transformation from iNHL to diffuse large B-cell lymphoma.
- •3. History of a non-lymphoma malignancy except for the following: adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, localized prostate cancer, other adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for =5 years.
- •4. Evidence of ongoing systemic bacterial, fungal, or viral infection (excluding viral upper respiratory tract infections) at the time of initiation of study treatment (Visit 2).
- •5. Pregnancy or breastfeeding.
- •6. Ongoing alcohol or drug addiction.
- •7. Known history of drug-induced liver injury, chronic active HCV, chronic active HBV, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, ongoing extrahepatic obstruction caused by stones, cirrhosis of the liver or portal hypertension.
- •8. History of prior allogeneic bone marrow progenitor cell or solid organ transplantation.
- •9. Ongoing immunosuppressive therapy, including systemic corticosteroids.
- •10. Prior therapy with CAL-101
- •11. Exposure to another investigational drug within 3 weeks prior to start of study treatment.
- •12. Concurrent participation in another therapeutic treatment trial.
- •13. Prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, ECG finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the patient; alter the absorption, distribution, metabolism or excretion of the study drug; or impair the assessment of study results.
研究者
相似试验
进行中（未招募）
1 期
Phase 2 Study of Idelalisib in Indolent B-Cell Non-Hodgkin LymphomaIndolent B-Cell Non-Hodgkin LymphomaMedDRA version: 20.0Level: PTClassification code 10029601Term: Non-Hodgkin's lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022155-33-DEGilead Sciences, Inc.120
进行中（未招募）
不适用
Efficacy and Safety of SM101 in the Treatment of IgA NephropathyIgA NephropathyMedDRA version: 18.0Level: PTClassification code 10021263Term: IgA nephropathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2015-002345-64-CZBaxalta Innovations GmbH51
招募中
不适用
A Phase 2 Study to Assess the Efficacy and Safety of CMX-020 in Treating Osteoarthritis.osteoarthritisACTRN12616001435471Cytometix A90
进行中（未招募）
不适用
A Phase 2 Study of CAL-101 in Indolent B-Cell Non-Hodgkin LymphomaEUCTR2010-022155-33-ITCALISTOGA PHARMACEUTICALS, INC.120
进行中（未招募）
1 期
A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients with Recurrent GliomasRecurrent glioblastoma or other brain cancer after failure of radiation therapy and temozolomideMedDRA version: 20.0Level: PTClassification code 10002224Term: Anaplastic astrocytomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073128Term: Anaplastic oligodendrogliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027769Term: Mixed oligo-astrocytomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10026659Term: Malignant oligodendrogliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003668-30-DKKaryopharm Therapeutic, Inc.76